

Accepted Manuscript

Title: Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma

Author: Yago Nieto, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Sairah Ahmed, Paolo Anderlini, Uday Popat, Roy B. Jones, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Partow Kebriaei, Amin Alousi, Melissa Timmons, Alison Gulbis, Alan Myers, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Sarah Milgrom, Richard Champlin, Borje S. Andersson


PII: S1083-8791(18)30106-X
DOI: <https://doi.org/10.1016/j.bbmt.2018.02.020>
Reference: YBBMT 55047

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 6-12-2017
Accepted date: 26-2-2018

Please cite this article as: Yago Nieto, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Sairah Ahmed, Paolo Anderlini, Uday Popat, Roy B. Jones, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Partow Kebriaei, Amin Alousi, Melissa Timmons, Alison Gulbis, Alan Myers, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Sarah Milgrom, Richard Champlin, Borje S. Andersson, Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma, *Biology of Blood and Marrow Transplantation* (2018), <https://doi.org/10.1016/j.bbmt.2018.02.020>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN'S LYMPHOMA

Yago Nieto (1), Peter F Thall (2), Junsheng Ma (2), Benigno C Valdez(1), Sairah Ahmed (1), Paolo Anderlini (1), Uday Popat (1), Roy B Jones (1), Elizabeth J Shpall (1), Chitra Hosing (1), Muzaffar Qazilbash (1), Partow Kebriaei (1), Amin Alousi (1), Melissa Timmons (1), Alison Gulbis (3), Alan Myers (3), Yasuhiro Oki (4), Michelle Fanale (4), Bouthaina Dabaja (5), Chelsea Pinnix (5), Sarah Milgrom (5), Richard Champlin (1), Borje S Andersson (1).

Departments of Stem Cell Transplantation and Cellular Therapy (1), Biostatistics (2), Pharmacy (3), Lymphoma and Myeloma (4) and Radiation Oncology (5), the University of Texas MD Anderson Cancer Center.

Corresponding Author:

Yago Nieto, MD

Department of Stem Cell Transplantation and Cellular Therapy, the University of Texas MD Anderson Cancer Center, Houston, TX. Phone: 713-792-2466. Fax: 713-794-4902

E-mail: ynieto@mdanderson.org

Running Title: High-dose Gem/Bu/Mel for poor-risk relapsed or refractory Hodgkin

Funding: Otsuka Pharmaceuticals, NCI P30 CA016672.

Conflict of Interest Disclosure:

YN reports research support for this trial from Otsuka Pharmaceuticals, and from Novartis Pharmaceuticals and Celgene Pharmaceuticals outside the submitted work. UP reports research support from Otsuka Pharmaceuticals outside the submitted work. RC reports research support from Sanofi and

Download English Version:

<https://daneshyari.com/en/article/8949645>

Download Persian Version:

<https://daneshyari.com/article/8949645>

[Daneshyari.com](https://daneshyari.com)